UNC Lineberger Comprehensive Cancer Center: Squamous Cell Carcinoma of Head and Neck trials

The registry lists 12 Squamous Cell Carcinoma of Head and Neck studies with UNC Lineberger Comprehensive Cancer Center as lead sponsor. 2 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 8No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)Not yet recruitingNCT07484139Phase 2
• Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCCRecruitingNCT04564989
• Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03174275Phase 2Results posted
• De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up StudyCompletedNCT02281955Phase 2Results posted
• Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHNCompletedNCT02124707Phase 2Results posted
• Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral SurgeryCompletedNCT01612351Phase 2Results posted
• De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell CaCompletedNCT01530997Phase 2Results posted
• Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT01412229Phase 2Results posted
• Pembrolizumab Plus Olaparib in LA-HNSCCActive, not recruitingNCT05366166Phase 2
• Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabSuspendedNCT04266730Phase 1
• Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCCCompletedNCT02585973Phase 1
• Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)TerminatedNCT02045186Not applicable